Asset
VITESPEN
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00126178 | phase3 | terminated | 2005-05-01 | 2006-03-01 | Agenus Inc. | Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer |
| NCT01147536 | phase2 | terminated | 2010-01-01 | 2012-06-01 | Agenus Inc. | Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence |
| NCT00098085 | phase2 | completed | 2003-09-01 | 2007-11-01 | Agenus Inc. | Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer |
FDA applications (0)
This company has no applications containing this asset.